NCT05647811: An ongoing trial by NovelMed Therapeutics
This trial is ongoing. It must report results 2 years, 2 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05647811 |
|---|---|
| Title | A Phase Ib, Open Label, Dose Escalation Study of NM8074 in Subjects with C3 Glomerulopathy (C3G) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 30, 2025 |
| Completion date | Feb. 28, 2027 |
| Required reporting date | Feb. 28, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |